We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

89 hedge funds and large institutions have $113M invested in Gyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more call options, than puts

Call options by funds: $2.92M | Put options by funds: $577K

117% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 18

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

25% more capital invested

Capital invested by funds: $90.2M → $113M (+$22.7M)

11% more funds holding

Funds holding: 80 → 89 (+9)

0.91% more ownership

Funds ownership: 8.63% → 9.54% (+0.91%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
39
Reduced
18
Closed
9
Calls
$2.92M
Puts
$577K
Net Calls
+$2.35M
Net Calls Change
+$2.02M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$12.9M
2
SCM
Stonepine Capital Management
Oregon
+$9.85M
3
OM
Opaleye Management
Massachusetts
+$6.71M
4
GTC
Ghost Tree Capital
New York
+$6.09M
5
NCM
Nantahala Capital Management
Connecticut
+$4.24M

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$2.66M
2
ACP
Acuta Capital Partners
California
-$2.55M
3
ACM
Altium Capital Management
New York
-$1.36M
4
Renaissance Technologies
Renaissance Technologies
New York
-$918K
5
Millennium Management
Millennium Management
New York
-$882K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
76
Panagora Asset Management
Massachusetts
$22K +$20K +438 +313%
LC
77
Lindbrook Capital
California
$20K +$24.4K +533 New
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$15K +$5.9K +129 +50%
TRCT
79
Tower Research Capital (TRC)
New York
$14K +$3.11K +68 +23%
Legal & General Group
80
Legal & General Group
United Kingdom
$14K +$4.07K +89 +33%
AIP
81
Ameritas Investment Partners
Nebraska
$8K – – –
FDCDDQ
82
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.67K – – –
CAGAS
83
Capital Advisory Group Advisory Services
Minnesota
$5K – – –
BCA
84
Berman Capital Advisors
Georgia
$4K – – –
CAPTRUST Financial Advisors
85
CAPTRUST Financial Advisors
North Carolina
$3K +$3.61K +79 New
JCM
86
Jacobi Capital Management
Pennsylvania
$1K +$1.23K +27 New
AIG
87
American International Group
New York
$90 +$31.2K +683 +40%
ACM
88
AIGH Capital Management
Maryland
– -$2.66M -56,139 Closed
Renaissance Technologies
89
Renaissance Technologies
New York
– -$918K -19,401 Closed
WVP
90
Worth Venture Partners
New Jersey
– -$627K -13,240 Closed
Connor, Clark & Lunn Investment Management (CC&L)
91
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$287K -6,055 Closed
Citadel Advisors
92
Citadel Advisors
Florida
– -$270K -5,909 Closed
VAM
93
Verity Asset Management
North Carolina
– -$171K -3,606 Closed
MAM
94
Marquette Asset Management
Minnesota
– -$41K -866 Closed
PWPS
95
Pinnacle Wealth Planning Services
Ohio
– -$5K -96 Closed
SNT
96
Security National Trust
West Virginia
– -$3K -62 Closed
1 2 3
4

GYRE Hedge Fund Activity: Q1 2021 in Review

89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2021, worth a combined $113M — up 25% from $90.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GYRE positions and 9 closed out — a net gain of 9 holders — while 39 added to existing stakes and 18 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $12.9M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.66M sold.

  • 89 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2021, up from 80 in Q4 2020.
  • Funds reported $113M of Gyre Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
  • 18 funds opened new Gyre Therapeutics positions in Q1 2021 and 9 closed out, a net change of +9 holders.
  • The largest Gyre Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $12.9M added.
  • The largest Gyre Therapeutics seller in Q1 2021 was AIGH Capital Management, an estimated $2.66M sold.

Based on aggregated 13F filings for Q1 2021.